CVX Vs XOM Stock, Which Energy Play Is Best?
Chevron (NYSE:CVX) and Exxon Mobil (NYSE:XOM) are two of the…
Sell
50
DRUG Quote, Financials, Valuation and Earnings
Last price:
$30.32
Seasonality move
:
10.59%
Day range:
$29.75 - $31.75
52-week range:
$0.93 - $79.02
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
5.26x
Volume:
27.5K
Avg. volume:
29.8K
1-year change:
2739.62%
Market cap:
$212M
Revenue:
--
EPS (TTM):
-$0.18
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
DRUG
Bright Minds Biosciences
|
-- | -$0.33 | -- | -233.48% | $93.12 |
|
NBY
NovaBay Pharmaceuticals
|
$3M | -$0.24 | 14.03% | -95.43% | $0.85 |
|
NNVC
Nanoviricides
|
-- | -$0.20 | -- | -26.67% | -- |
|
OGEN
Oragenics
|
-- | -- | -- | -- | $1.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics
|
-- | -$5.50 | -- | -8.25% | $6.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
DRUG
Bright Minds Biosciences
|
$30.10 | $93.12 | $212M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals
|
$0.58 | $0.85 | $3.4M | -- | $0.00 | 0% | 0.16x |
|
NNVC
Nanoviricides
|
$1.26 | -- | $19.7M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics
|
$0.18 | $1.00 | $3.9M | -- | $0.00 | 0% | 1.12x |
|
PTN
Palatin Technologies
|
$0.17 | -- | $4.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics
|
$1.36 | $6.00 | $3.8M | -- | $0.00 | 0% | 0.63x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
DRUG
Bright Minds Biosciences
|
-- | -61.227 | -- | -- |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | -0.186 | 1.51% | 0.75x |
|
NNVC
Nanoviricides
|
-- | 2.080 | -- | -- |
|
OGEN
Oragenics
|
-- | 3.254 | -- | -- |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics
|
-- | -2.512 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
DRUG
Bright Minds Biosciences
|
-- | -$1.2M | -- | -- | -- | -$1.1M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$1.1M | -334.47% | -461.38% | -44% | -$2.1M |
|
NNVC
Nanoviricides
|
-- | -$2.1M | -- | -- | -- | -$2.2M |
|
OGEN
Oragenics
|
-- | -$3.4M | -- | -- | -- | -$2M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics
|
-- | -$4.6M | -- | -- | -- | -$4.7M |
Bright Minds Biosciences vs. Competitors
-
Which has Higher Returns DRUG or NBY?
NovaBay Pharmaceuticals has a net margin of -- compared to Bright Minds Biosciences's net margin of -49.65%. Bright Minds Biosciences's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital DRUGBright Minds Biosciences-- $0.01 -- NBYNovaBay Pharmaceuticals65.26% -$0.60 $1.1M -
What do Analysts Say About DRUG or NBY?
Bright Minds Biosciences has a consensus price target of $93.12, signalling upside risk potential of 209.38%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 46.43%. Given that Bright Minds Biosciences has higher upside potential than NovaBay Pharmaceuticals, analysts believe Bright Minds Biosciences is more attractive than NovaBay Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings DRUGBright Minds Biosciences2 0 0 NBYNovaBay Pharmaceuticals1 0 0 -
Is DRUG or NBY More Risky?
Bright Minds Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.
-
Which is a Better Dividend Stock DRUG or NBY?
Bright Minds Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bright Minds Biosciences pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DRUG or NBY?
Bright Minds Biosciences quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Bright Minds Biosciences's net income of $35.3K is higher than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Bright Minds Biosciences's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bright Minds Biosciences is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DRUGBright Minds Biosciences-- -- -- $35.3K NBYNovaBay Pharmaceuticals0.16x -- $2.4M -$1.2M
-
Which has Higher Returns DRUG or NNVC?
Nanoviricides has a net margin of -- compared to Bright Minds Biosciences's net margin of --. Bright Minds Biosciences's return on equity of -- beat Nanoviricides's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital DRUGBright Minds Biosciences-- $0.01 -- NNVCNanoviricides-- -$0.14 -- -
What do Analysts Say About DRUG or NNVC?
Bright Minds Biosciences has a consensus price target of $93.12, signalling upside risk potential of 209.38%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 415.42%. Given that Nanoviricides has higher upside potential than Bright Minds Biosciences, analysts believe Nanoviricides is more attractive than Bright Minds Biosciences.
Company Buy Ratings Hold Ratings Sell Ratings DRUGBright Minds Biosciences2 0 0 NNVCNanoviricides0 0 0 -
Is DRUG or NNVC More Risky?
Bright Minds Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.947, suggesting its less volatile than the S&P 500 by 5.32%.
-
Which is a Better Dividend Stock DRUG or NNVC?
Bright Minds Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bright Minds Biosciences pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DRUG or NNVC?
Bright Minds Biosciences quarterly revenues are --, which are smaller than Nanoviricides quarterly revenues of --. Bright Minds Biosciences's net income of $35.3K is higher than Nanoviricides's net income of -$2M. Notably, Bright Minds Biosciences's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bright Minds Biosciences is -- versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DRUGBright Minds Biosciences-- -- -- $35.3K NNVCNanoviricides-- -- -- -$2M
-
Which has Higher Returns DRUG or OGEN?
Oragenics has a net margin of -- compared to Bright Minds Biosciences's net margin of --. Bright Minds Biosciences's return on equity of -- beat Oragenics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital DRUGBright Minds Biosciences-- $0.01 -- OGENOragenics-- -$0.27 -- -
What do Analysts Say About DRUG or OGEN?
Bright Minds Biosciences has a consensus price target of $93.12, signalling upside risk potential of 209.38%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 457.73%. Given that Oragenics has higher upside potential than Bright Minds Biosciences, analysts believe Oragenics is more attractive than Bright Minds Biosciences.
Company Buy Ratings Hold Ratings Sell Ratings DRUGBright Minds Biosciences2 0 0 OGENOragenics0 1 0 -
Is DRUG or OGEN More Risky?
Bright Minds Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics has a beta of 1.161, suggesting its more volatile than the S&P 500 by 16.138%.
-
Which is a Better Dividend Stock DRUG or OGEN?
Bright Minds Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bright Minds Biosciences pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DRUG or OGEN?
Bright Minds Biosciences quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. Bright Minds Biosciences's net income of $35.3K is higher than Oragenics's net income of -$3.3M. Notably, Bright Minds Biosciences's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bright Minds Biosciences is -- versus 1.12x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DRUGBright Minds Biosciences-- -- -- $35.3K OGENOragenics1.12x -- -- -$3.3M
-
Which has Higher Returns DRUG or PTN?
Palatin Technologies has a net margin of -- compared to Bright Minds Biosciences's net margin of --. Bright Minds Biosciences's return on equity of -- beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital DRUGBright Minds Biosciences-- $0.01 -- PTNPalatin Technologies-- -- -- -
What do Analysts Say About DRUG or PTN?
Bright Minds Biosciences has a consensus price target of $93.12, signalling upside risk potential of 209.38%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 4017.65%. Given that Palatin Technologies has higher upside potential than Bright Minds Biosciences, analysts believe Palatin Technologies is more attractive than Bright Minds Biosciences.
Company Buy Ratings Hold Ratings Sell Ratings DRUGBright Minds Biosciences2 0 0 PTNPalatin Technologies0 0 0 -
Is DRUG or PTN More Risky?
Bright Minds Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock DRUG or PTN?
Bright Minds Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bright Minds Biosciences pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DRUG or PTN?
Bright Minds Biosciences quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of --. Bright Minds Biosciences's net income of $35.3K is higher than Palatin Technologies's net income of --. Notably, Bright Minds Biosciences's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bright Minds Biosciences is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DRUGBright Minds Biosciences-- -- -- $35.3K PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns DRUG or TOVX?
Theriva Biologics has a net margin of -- compared to Bright Minds Biosciences's net margin of --. Bright Minds Biosciences's return on equity of -- beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital DRUGBright Minds Biosciences-- $0.01 -- TOVXTheriva Biologics-- -$1.60 -- -
What do Analysts Say About DRUG or TOVX?
Bright Minds Biosciences has a consensus price target of $93.12, signalling upside risk potential of 209.38%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 341.18%. Given that Theriva Biologics has higher upside potential than Bright Minds Biosciences, analysts believe Theriva Biologics is more attractive than Bright Minds Biosciences.
Company Buy Ratings Hold Ratings Sell Ratings DRUGBright Minds Biosciences2 0 0 TOVXTheriva Biologics0 0 0 -
Is DRUG or TOVX More Risky?
Bright Minds Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.
-
Which is a Better Dividend Stock DRUG or TOVX?
Bright Minds Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bright Minds Biosciences pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DRUG or TOVX?
Bright Minds Biosciences quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Bright Minds Biosciences's net income of $35.3K is higher than Theriva Biologics's net income of -$4.4M. Notably, Bright Minds Biosciences's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bright Minds Biosciences is -- versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DRUGBright Minds Biosciences-- -- -- $35.3K TOVXTheriva Biologics0.63x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is it Safe to Invest in Google With OpenAI Threats?
For the last 20 years, Google parent company Alphabet (NASDAQ:GOOG,…
Is Broadcom Stock a Millionaire Maker?
Broadcom (Nasdaq: AVGO) stock has gone up more than 64%…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Buy
60
RGC alert for May 8
Regencell Bioscience Holdings [RGC] is up 22.52% over the past day.
Buy
52
SRPT alert for May 8
Sarepta Therapeutics [SRPT] is down 21.54% over the past day.
Buy
74
LIVN alert for May 8
LivaNova PLC [LIVN] is up 23.38% over the past day.
